Cervical cancer2023

แชร์
ฝัง
  • เผยแพร่เมื่อ 26 ธ.ค. 2024

ความคิดเห็น • 9

  • @missormocana
    @missormocana ปีที่แล้ว +1

    wooow doc this is really informative-Gladys here your Medical assistant!!!

  • @slmerts9955
    @slmerts9955 5 หลายเดือนก่อน +1

    thank u soooo much

  • @toto244_
    @toto244_ ปีที่แล้ว +1

    Thanks dear doctor for informative lectures ,I benefit alot Iam medical oncology SHO in Iraq....

  • @denislarinov1900
    @denislarinov1900 ปีที่แล้ว +1

    Dear Dr. Kim, in your slide about radiation treatment, I noticed an inaccuracy in EBRT doses: 45 Gy= 4500 cGy =1 ,8 Gy x 25 Fx. You have written 45 cGy (is only 0,45 Gy x 25 Fx = 11.25 Gy)

  • @stanleykim1924
    @stanleykim1924  2 หลายเดือนก่อน

    Pembrolizumab Plus Chemoradiotherapy Provides Significant Survival Benefit in Cervical Cancer
    Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer, according to results of a phase 3, randomized, double-blind trial.
    Domenica Lorusso, MD, PhD, director of Gynecological Oncology at Humanitas San Pio X and professor at Humanitas University, Milan, Italy, presented these findings of the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study at the European Society for Medical Oncology (ESMO) Annual Meeting 2024. The results were published online ahead of print in The Lancet on the day of the presentation.
    "For more than 20 years, the standard treatment of locally advanced cervical cancer has been concurrent chemoradiation plus brachytherapy, based on the results of five randomized trials that reported a 6% increase in overall survival when we combined chemotherapy with radiation," Lorusso said.
    The study enrolled 1060 patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, defined as FIGO 2014 stage IB2-IIB with node-positive disease or stage III-IVA regardless of the lymph node status.
    Patients were randomized 1:1 to receive either pembrolizumab or placebo in combination with standard CCRT. Patients in the pembrolizumab arm received 200 mg every 3 weeks for five cycles during CCRT, followed by 400 mg every 6 weeks for 15 cycles.
    According to Lorusso, the trial is particularly notable for its use of modern radiotherapy techniques. Over 85% patients were treated with intensity-modulated external beam radiotherapy, and a similar proportion received volume-based brachytherapy, she said.
    The median total equivalent dose in 2-Gy fraction (EQD2 dose) to the high-risk clinical target volume was 87 Gy.
    R.A. Nout, MD, PhD, professor of radiotherapy at Erasmus MC, Rotterdam, the Netherlands, said giving this dose reflects contemporary best practices in radiation oncology for cervical cancer.
    At a median follow-up of 29.9 months (range, 12.8-43.0 months), the study met its primary endpoint, demonstrating a statistically significant improvement in overall survival with pembrolizumab plus CCRT vs placebo plus CCRT. The 36-month overall survival rate was 82.6% in the pembrolizumab arm vs 74.8% in the placebo arm (hazard ratio [HR], 0.67; 95% CI, 0.50-0.90; P = .0040).
    Lorusso emphasized the clinical significance of these results: "A statistically significant and [clinically] meaningful overall survival benefit was reported in patients treated with pembrolizumab, with a hazard ratio of 0.67, suggesting a 33% reduction in the risk of death."
    The benefit of pembrolizumab was consistent across prespecified subgroups, including FIGO stages IB2-IIB (HR, 0.89; 95% CI, 0.55-1.44) and III-IVA (HR, 0.57; 95% CI, 0.39-0.83).
    Progression-free survival (PFS), a co-primary endpoint, also showed significant improvement. At 2 years, 67% patients in the pembrolizumab arm were free of progression compared with 57% patients in the placebo arm (HR, 0.65; 95% CI, 0.53-0.79; P < .0001).
    According to Lorusso, the safety profile of pembrolizumab plus CCRT was manageable and consistent with known toxicities of the individual therapies. Grade ≥ 3 treatment-related adverse events occurred in 69.1% patients in the pembrolizumab group vs 61.3% patients in the placebo group. Immune-related adverse events were more common with pembrolizumab (40% vs 17%) but were mostly grade 1-2.
    During her talk, Lorusso emphasized that none of the patients experienced colitis. "We pay particular attention to digestive adverse events because of possible overlapping toxicity of immune-related colitis post-radiotherapy colitis," she explained.
    Commenting on the clinical implications of their findings, Lorusso stated, "In our opinion, these data support pembrolizumab in combination with chemoradiation as the new standard of care in patients with locally advanced high-risk cervical cancer."